Antibody

Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board

Retrieved on: 
Wednesday, September 7, 2022

"I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."

Key Points: 
  • "I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."
  • "Biosion's SynTracer internalization platform is uniquely positioned to deliver fit-for-purpose monoclonal antibodies for ADC candidates, a next generation approach to targeting cancer."
  • Dr. Dixit was honored in 2020 by the World ADC Forum with its most prestigious award of Long Standing Contributor to ADCs.
  • Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and phase-I for atopic dermatitis.

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

Retrieved on: 
Wednesday, September 7, 2022

Group B Streptococcus (GBS) is a common bacterium that can cause potentially devastating diseases in infants, including sepsis, pneumonia and meningitis, during the first three months of life.

Key Points: 
  • Group B Streptococcus (GBS) is a common bacterium that can cause potentially devastating diseases in infants, including sepsis, pneumonia and meningitis, during the first three months of life.
  • Vaccines given to pregnant women (maternal immunization) that are intended to prevent illness in young infants rely on this process of transplacental antibody transfer.
  • A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
  • Group B Streptococcus infection causes an estimated 150,000 preventable stillbirths and infant deaths every year.

Global Liver Disease Treatment Market Report 2022-2027: Rise in Incidence of Liver Diseases & Increase in Government and Non-government Awareness Programs Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022

Market dynamics are forces that impact the prices and behaviors of the Global Liver Disease Treatment Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global Liver Disease Treatment Market stakeholders.
  • The Global Liver Disease Treatment Market is segmented based on Disease, Treatment, and Geography.
  • By Disease, the market is classified into Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, and Others.
  • The report presents a detailed Ansoff matrix analysis for the Global Liver Disease Treatment Market.

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

Retrieved on: 
Tuesday, September 6, 2022

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.
  • Additionally, patients reported improved health status, as measured by St. Georges Respiratory Questionnaire-Total and -Activity, when compared with placebo-treated patients .
  • Abstract #1154: Safety and Tolerability of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) presented by F. Bonella, M.D., Ph.D.
  • Additionally, the posters are scheduled to be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.

Adagio Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 6, 2022

H.C. Wainwright 24th Annual Global Investment Conference: Management will participate in 1 on 1 meetings on Tuesday, September 13, 2022.

Key Points: 
  • H.C. Wainwright 24th Annual Global Investment Conference: Management will participate in 1 on 1 meetings on Tuesday, September 13, 2022.
  • A live webcast of the fireside chat will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 90 days following the presentations.
  • Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases.
  • The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.

Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer

Retrieved on: 
Tuesday, September 6, 2022

BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to Chief Executive Officer (CEO), President and member of the Board of Directors. He is succeeding Arthur Tzianabos, Ph.D., who has been appointed as Chairperson of Homology’s Board of Directors. Dr. Tzianabos and Dr. Seymour joined Homology in 2016 as CEO & President and Chief Scientific Officer, respectively, and they helped to build the Company into a clinical-stage organization with programs spanning nuclease-free gene editing, gene therapy and gene therapy-delivered monoclonal antibodies (GTx-mAb).

Key Points: 
  • BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to Chief Executive Officer (CEO), President and member of the Board of Directors.
  • We believe Homology has a clear path forward with our clinical programs and is in a strong financial position.
  • Albert is a seasoned scientific executive who has also led Clinical Development and Operations, Commercial and Human Resources at the Company.
  • Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease.

Orum Therapeutics to Participate at Investor Conferences in September

Retrieved on: 
Tuesday, September 6, 2022

Orum Therapeutics , a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Companys leadership will participate in the following investor conferences:

Key Points: 
  • Orum Therapeutics , a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Companys leadership will participate in the following investor conferences:
    The presentation will take place at 4:20 pm ET on September 13th.
  • The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway.
  • Orum Therapeutics is a private, clinical stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD approach to provide dual-precision, antibody-enabled targeted protein degraders for cell-specific delivery.
  • The Companys proprietary platforms generated using the TPD approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates.

Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare

Retrieved on: 
Tuesday, September 6, 2022

PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) announced today the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%. Glioblastoma multiforme (GBM) is a deadly type of brain tumor and 5-year survival is just 8% for those aged 45-54. About 25% of GBM patients are not actively treated due to rapid disease progression. Malignant melanoma, the most serious skin cancer, can metastasize to other organs. Once it has spread to other organs it is difficult to treat. Metastatic melanoma (Stage IV) has 22.5% five year survival. Non-small cell lung cancer (NSCLC) is a major unmet medical need that accounts for 85% of pulmonary malignancies and effects approximately 450,000 individuals. In greater than 50% of affected patients the tumors are diagnosed at advanced stages with metastatic spread that precludes curative surgical resection.

Key Points: 
  • Antibodies that target ICPI such as PD-1, PD-L1 and CTLA4 have been generated which have therapeutic efficacy in NSCLC and other tumors.
  • The impressive ability of our bispecific antibodies to control primary and metastatic lung cancer in murine experimental modeling systems is discussed below.
  • In the coculture system, critical immune regulating cells called T cells were placed in culture with cancer cells.
  • Neither of Ocean Biomedical or Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Retrieved on: 
Tuesday, September 6, 2022

The trial will evaluate Immuteps lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).

Key Points: 
  • The trial will evaluate Immuteps lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).
  • Immutep will provide efti at no cost to the Maria Skodowska-Curie National Research Institute of Oncology and will technically support the trial.
  • The trial will be led by Principal Investigators, Dr. Katarzyna Kozak, M.D.
  • PhD., and Pawe Sobczuk, M.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skodowska-Curie National Research Institute of Oncology.

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

Retrieved on: 
Tuesday, September 6, 2022

Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II.

Key Points: 
  • Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II.
  • Chembio has previous experience in the field of rapid syphilis diagnostics through its successful development, validation, and commercialization of DPP HIV-Syphilis.
  • The Chembio DPP HIV-Syphilis Assay is a rapid serologic test for the detection of antibodies to HIV and/or the causative agent of syphilis, Treponema pallidum.
  • Additionally, Chembio has worked to develop a DPP Syphilis Screen and Confirm test, using a CDC licensed reagent with improved liposomal preparation on the nontreponemal test line.